Top Markets
Coin of the day
Vaxil Bio Ltd. Vaxil Bio Ltd.

Vaxil Bio Ltd.

VXL
株式のランク #39496
Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing... Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.
株価
$0.1174299
最終同期: 2026-08-13
時価総額
$467.84K
変化(1日)
-8.57%
変化(1年)
1.38%
CA
取引 Vaxil Bio Ltd. (VXL)

カテゴリー

Vaxil Bio Ltd.(VXL)のP/B比率
2026 時点のP/B比率 TTM: 0
Vaxil Bio Ltd. の最新の財務報告および株価によると、現在のP/B比率(TTM)は 0 です。2026 年末時点でのP/B比率は 0 でした。
Vaxil Bio Ltd. の P/B 比率の履歴(2026 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE